CN110916184A - Health product with function of relaxing bowels and preparation method thereof - Google Patents
Health product with function of relaxing bowels and preparation method thereof Download PDFInfo
- Publication number
- CN110916184A CN110916184A CN201911248849.XA CN201911248849A CN110916184A CN 110916184 A CN110916184 A CN 110916184A CN 201911248849 A CN201911248849 A CN 201911248849A CN 110916184 A CN110916184 A CN 110916184A
- Authority
- CN
- China
- Prior art keywords
- parts
- health product
- function
- sieving
- fructus cannabis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036541 health Effects 0.000 title claims abstract description 36
- 230000002040 relaxant effect Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 20
- 241000132012 Atractylodes Species 0.000 claims abstract description 19
- 235000006533 astragalus Nutrition 0.000 claims abstract description 19
- 210000000582 semen Anatomy 0.000 claims abstract description 13
- 244000134552 Plantago ovata Species 0.000 claims abstract description 12
- 235000003421 Plantago ovata Nutrition 0.000 claims abstract description 12
- 239000010903 husk Substances 0.000 claims abstract description 9
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 5
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 5
- 239000000047 product Substances 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 206010010774 Constipation Diseases 0.000 claims description 31
- 238000002156 mixing Methods 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 23
- 241000218236 Cannabis Species 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 20
- 238000007873 sieving Methods 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 15
- 241000125175 Angelica Species 0.000 claims description 14
- 241001061264 Astragalus Species 0.000 claims description 14
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 14
- 235000003805 Musa ABB Group Nutrition 0.000 claims description 14
- 241001127637 Plantago Species 0.000 claims description 14
- 235000015266 Plantago major Nutrition 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 14
- 210000004233 talus Anatomy 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 10
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 10
- 229920002774 Maltodextrin Polymers 0.000 claims description 9
- 239000005913 Maltodextrin Substances 0.000 claims description 9
- 239000004376 Sucralose Substances 0.000 claims description 9
- 229940035034 maltodextrin Drugs 0.000 claims description 9
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 9
- 235000019408 sucralose Nutrition 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 239000007779 soft material Substances 0.000 claims description 8
- 239000009636 Huang Qi Substances 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 235000008216 herbs Nutrition 0.000 claims 2
- 230000013872 defecation Effects 0.000 abstract description 16
- 210000000813 small intestine Anatomy 0.000 abstract description 13
- 230000001737 promoting effect Effects 0.000 abstract description 10
- 230000005176 gastrointestinal motility Effects 0.000 abstract description 2
- 240000004308 marijuana Species 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 28
- 230000006870 function Effects 0.000 description 22
- 239000000976 ink Substances 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- -1 compound diphenoxylate Chemical class 0.000 description 12
- 229960004192 diphenoxylate Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 239000008141 laxative Substances 0.000 description 9
- 230000001543 purgative effect Effects 0.000 description 8
- 235000010489 acacia gum Nutrition 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 230000008991 intestinal motility Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 241000167854 Bourreria succulenta Species 0.000 description 6
- 241000612118 Samolus valerandi Species 0.000 description 6
- 235000019693 cherries Nutrition 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 5
- OKTJSMMVPCPJKN-YPZZEJLDSA-N carbon-10 atom Chemical compound [10C] OKTJSMMVPCPJKN-YPZZEJLDSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000001187 pylorus Anatomy 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000011229 interlayer Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 241000555745 Sciuridae Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000713 mesentery Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000000105 enteric nervous system Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229940076742 senna leaves Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a health product with a function of relaxing bowels and a preparation method thereof, wherein the health product is prepared from 100-300 parts of angelica sinensis, 200-600 parts of astragalus membranaceus, 150-450 parts of bighead atractylodes rhizome, 150-450 parts of Plantago ovata seed husk, 250-750 parts of fructus cannabis, 100-300 parts of semen cassiae and the like. The health product provided by the invention has the effects of promoting the small intestine to push and empty, promoting the gastrointestinal motility and having a good defecation promoting effect.
Description
Technical Field
The invention relates to a health-care product, in particular to a health-care product with a function of relaxing bowels and a preparation method thereof.
Background
Defecation disorder and chronic functional constipation are common clinical symptoms, and the incidence rate of the constipation is on the rising trend year by year along with the development of a series of factors such as the increase of living pressure, the acceleration of rhythm, the change of diet and the like of people. The disease brings much pain to patients with constipation, and also increases the incidence of diseases such as colon cancer, hepatic encephalopathy, breast diseases, presenile dementia and the like. Constipation can even directly endanger the life of a patient by inducing an acute myocardial infarction or cerebrovascular accident. Clinical treatment lacks systematic and comprehensive treatment, and the effect is not satisfactory, because the disease is also related to a plurality of factors such as diet, occupation, heredity, medicine, cultural degree, geographical distribution, residential areas, marital, character, mental state and the like. Therefore, the treatment of constipation is receiving more and more attention.
At present, the clinical treatment methods for constipation mainly comprise the following methods:
general treatment: by changing the life style and increasing the amount of exercise and dietary fiber, the constipation has little effect on intractable constipation and needs to be treated by matching with medicines. Laxative treatment: prokinetic therapy and traditional Chinese medicine therapy, etc. From the clinical patients, intractable constipation appears due to the use of a large amount of purgative, the current market is inundated with purgative drugs, such as various bowel-clearing tea, toxin-expelling and face-nourishing capsules, senna leaves and the like, the main components of the purgative drugs are anthraquinone drugs, most patients mainly rely on purgative to defecate due to the advertising effect, the patients take the drugs for months or even years, but the dosage of the purgative is larger and the effect is poorer and poorer along with the prolonging of time, and finally the purgative cannot be defecated even though the purgative is connected, and the purgative can cause benign reversible colon pigmentation, damage the enteric nervous system due to the long-term use, cause intestinal motility disorder and form colon slow-transmission constipation.
Therefore, it is necessary to research a health care product which is safe to take, has small toxic and side effects, has a good function of relaxing the bowels and treats constipation under the guidance of the theory of traditional Chinese medicine.
Disclosure of Invention
The purpose of the invention is as follows: the invention aims to overcome the defects of the prior art and provide the health-care product which is safe to take, has small side effect, and has good bowel relaxing function and constipation treating effect.
The technical scheme is as follows: in order to achieve the above purpose, the invention adopts the technical scheme that:
a health product with a function of relaxing bowels is characterized by comprising the following raw materials in parts by weight:
angelica, astragalus, bighead atractylodes rhizome, fructus cannabis, semen cassiae and plantain seed shell.
As a preferred scheme, the health care product with the function of relaxing the bowels comprises the following raw materials in parts by weight:
100-300 parts of angelica sinensis, 200-600 parts of astragalus membranaceus, 150-450 parts of bighead atractylodes rhizome, 150-450 parts of Plantago ovata forsk, 250-750 parts of fructus cannabis and 100-300 parts of semen cassiae.
As a preferred scheme, the health care product with the function of relaxing the bowels comprises the following raw materials in parts by weight:
100 parts of angelica, 200 parts of astragalus, 150 parts of bighead atractylodes rhizome, 150 parts of plantain seed shell, 250 parts of fructus cannabis and 100 parts of cassia seed.
As a preferred scheme, the health care product with the function of relaxing the bowels comprises the following raw materials in parts by weight:
300 parts of angelica, 600 parts of astragalus, 450 parts of bighead atractylodes rhizome, 450 parts of plantain seed husk, 750 parts of fructus cannabis and 300 parts of cassia seed.
As a preferred scheme, the health care product with the function of relaxing the bowels comprises the following raw materials in parts by weight:
200 parts of angelica, 400 parts of astragalus, 300 parts of bighead atractylodes rhizome, 300 parts of plantain seed shell, 500 parts of fructus cannabis and 200 parts of cassia seed.
A health product with a function of relaxing bowels is prepared by the following method: (1) decocting radix Angelicae sinensis, radix astragali, Atractylodis rhizoma, fructus Cannabis and semen Cassiae in water, filtering, and mixing filtrates; concentrating under reduced pressure to obtain soft extract;
(2) taking the thick paste prepared in the step (1), drying under reduced pressure, crushing and sieving with a 80-mesh sieve for later use;
(3) respectively pulverizing Plantago ovata forsk, sucralose and maltodextrin, sieving with 80 mesh sieve, and mixing;
(4) uniformly mixing the extract powder of the medicinal materials in the step (2) and the powder in the step (3); then adding ethanol to prepare soft material, sieving and granulating, drying, grading, and preparing to obtain the granule.
Preferably, the preparation method of the health product with the function of relaxing bowels comprises the following steps:
(1) extracting radix Angelicae sinensis, radix astragali, Atractylodis rhizoma, fructus Cannabis and semen Cassiae with water, filtering, and mixing filtrates; concentrating under reduced pressure to obtain soft extract;
(2) taking the thick paste prepared in the step (1), drying under reduced pressure, crushing and sieving for later use;
(3) pulverizing Plantago ovata forsk, sucralose and maltodextrin respectively, sieving, and mixing;
(4) uniformly mixing the extract powder of the medicinal materials in the step (2) and the powder in the step (3); then adding ethanol to prepare soft material, sieving and granulating, drying, grading, and preparing to obtain the granule.
More preferably, the preparation method of the health product with the function of relaxing bowels comprises the following steps:
(1) firstly, extracting angelica sinensis, astragalus membranaceus, bighead atractylodes rhizome, fructus cannabis and semen cassiae with 6-15 times of water for 1-3 times, 1-2 hours each time, filtering, and combining filtrates; concentrating under reduced pressure to obtain soft extract;
(2) taking the thick paste prepared in the step (1), drying under reduced pressure, crushing, and sieving with a 80-100-mesh sieve for later use;
(3) respectively crushing Plantago ovata forsk, sucralose and maltodextrin, sieving with a sieve of 80-100 meshes, and uniformly mixing;
(4) uniformly mixing the extract powder of the medicinal materials in the step (2) and the powder in the step (3); then adding ethanol with volume concentration of 85% to prepare soft materials, granulating with 14-mesh sieve, drying, grading with 12-mesh sieve, and preparing into granule.
As a more preferable scheme, in the above preparation method of the health product with the function of relaxing bowels, in the step (1), water with the weight 10 times of the total weight of the medicinal materials is added for the first time, the decoction, the reflux or the continuous reflux extraction is carried out for 1.5 hours, water with the weight 8 times of the total weight of the medicinal materials is added for the second time, the reflux or the continuous reflux extraction is carried out for 1.5 hours, the two decoctions are combined, the filtration is carried out, and the filtrates are combined; concentrating under reduced pressure to obtain a thick paste with the relative density of 1.25-1.30 at 50 ℃.
Preferably, in the preparation method of the health product with the function of relaxing bowels, the step (2) and the step (3) are both sieved by a 80-mesh sieve.
Has the advantages that: compared with the prior art, the health product with the function of relaxing the bowels and the preparation method thereof have the following advantages:
the health product with the function of relaxing bowels selects raw materials to be compatible and formulated according to the traditional Chinese medicine theory and the pathogenesis of constipation, particularly, the plantain seed husk powder added in the health product is mixed with the traditional Chinese medicine according to a specific proportion, so that the coordination and synergism effects can be achieved, the proportion of the components is scientific and reasonable, and the experimental result shows that the health product has the effects of promoting small intestine propulsion and emptying movement, promoting gastrointestinal motility and having a good defecation promoting effect.
Drawings
FIG. 1 is a bar graph of the effect on intestinal transit in mice.
FIG. 2 is a bar graph of the time to first stool for mice.
Detailed Description
The invention will be better understood from the following examples. However, those skilled in the art will readily appreciate that the specific material ratios, process conditions and results thereof described in the examples are illustrative only and should not be taken as limiting the invention as detailed in the claims.
Example 1
1. A health product with a function of relaxing bowels is prepared from the following raw materials in parts by weight:
100 parts of angelica, 200 parts of astragalus, 150 parts of bighead atractylodes rhizome, 150 parts of plantain seed shell, 250 parts of fructus cannabis and 100 parts of cassia seed.
2. The preparation method of the health care product with the function of relaxing bowels comprises the following steps:
(1) taking 100 parts of angelica, 200 parts of astragalus, 150 parts of bighead atractylodes rhizome, 250 parts of fructus cannabis and 100 parts of semen cassiae; adding water with the weight 10 times of the total weight of the medicinal materials for the first time, decocting for 1.5 hours, adding water with the weight 8 times of the total weight of the medicinal materials for the second time, decocting for 1.5 hours, combining decoctions for the second time, filtering, and concentrating under reduced pressure (the temperature is less than or equal to 70 ℃, the vacuum degree is-0.06 Mpa to-0.08 Mpa) until the relative density is 1.25 to 1.30(50 ℃), thus obtaining thick paste;
(2) taking the thick paste prepared in the step (1), and drying under reduced pressure (the temperature is less than or equal to 70 ℃, and the vacuum degree is between-0.06 Mpa and-0.08 Mpa) for later use;
(3) respectively crushing 150 parts of Plantago ovata forsk husk, 3 parts of sucralose and 250 parts of maltodextrin, sieving with a 80-mesh sieve, and uniformly mixing;
(4) uniformly mixing the extract powder of the medicinal materials in the step (2) and the powder in the step (3); then adding ethanol with volume concentration of 85% to prepare soft materials, granulating with 14-mesh sieve, drying, grading with 12-mesh sieve, and preparing into granule.
Example 2
1. A health product with a function of relaxing bowels is prepared from the following raw materials in parts by weight:
300 parts of angelica, 600 parts of astragalus, 450 parts of bighead atractylodes rhizome, 450 parts of plantain seed husk, 750 parts of fructus cannabis and 300 parts of cassia seed.
2. The preparation method of the health care product with the function of relaxing bowels comprises the following steps:
(1) taking 300 parts of angelica, 600 parts of astragalus, 450 parts of bighead atractylodes rhizome, 750 parts of fructus cannabis and 300 parts of semen cassiae; adding water with the weight being 12 times of the total weight of the medicinal materials for the first time, decocting for 2 hours, adding water with the weight being 10 times of the total weight of the medicinal materials for the second time, decocting for 1 hour, combining decoction liquids of the second time, filtering, and concentrating under reduced pressure (the temperature is less than or equal to 70 ℃, the vacuum degree is between-0.06 Mpa and-0.08 Mpa) until the relative density is between 1.25 and 1.30(50 ℃), thus obtaining thick paste;
(2) taking the thick paste prepared in the step (1), and drying under reduced pressure (the temperature is less than or equal to 70 ℃, and the vacuum degree is between-0.06 Mpa and-0.08 Mpa) for later use;
(3) respectively crushing 450 parts of Plantago ovata forsk husk, 9 parts of sucralose and 750 parts of maltodextrin, sieving with a 80-mesh sieve, and uniformly mixing;
(4) uniformly mixing the extract powder of the medicinal materials in the step (2) and the powder in the step (3); adding 85% ethanol, drying, adding lactose or corn starch as carrier, adding magnesium stearate as lubricant, mixing, and tabletting.
Example 3 control group
1. A health product with a function of relaxing bowels is prepared from the following raw materials in parts by weight:
100 parts of angelica, 200 parts of astragalus, 150 parts of bighead atractylodes rhizome, 250 parts of fructus cannabis, 100 parts of cassia seed and 150 parts of bunge cherry seed.
2. The preparation method of the health care product with the function of relaxing bowels comprises the following steps:
(1) 100 parts of angelica, 200 parts of astragalus, 150 parts of bighead atractylodes rhizome, 250 parts of fructus cannabis, 100 parts of cassia seed and 150 parts of bunge cherry seed; adding water with the weight 10 times of the total weight of the medicinal materials for the first time, decocting for 1.5 hours, adding water with the weight 8 times of the total weight of the medicinal materials for the second time, decocting for 1.5 hours, combining decoctions for the second time, filtering, and concentrating under reduced pressure (the temperature is less than or equal to 70 ℃, the vacuum degree is-0.06 Mpa to-0.08 Mpa) until the relative density is 1.25 to 1.30(50 ℃), thus obtaining thick paste;
(2) taking the thick paste prepared in the step (1), and drying under reduced pressure (the temperature is less than or equal to 70 ℃, and the vacuum degree is between-0.06 Mpa and-0.08 Mpa) for later use;
(3) 3 parts of sucralose and 250 parts of maltodextrin, respectively crushing, sieving with a 80-mesh sieve, and uniformly mixing;
(4) uniformly mixing the extract powder of the medicinal materials in the step (2) and the powder in the step (3); then adding ethanol with volume concentration of 85% to prepare soft materials, granulating with 14-mesh sieve, drying, grading with 12-mesh sieve, and preparing into granule.
Example 4 study of drug efficacy
1 Material
1.1 medicine: test group: the dry powder of step (3) of example 1 of the present invention. Control group: example 3 dried powder of step (2).
1.2 animals: the male Kunming mouse is purchased from the experimental animal center of the medical college of Xian traffic university, the weight is 18-22g, and the production license number is: SCXK (shan) 2018-. Animal feed bedding materials are as above. The test animal house is a barrier system, and the use license number: SCXK (shan) 2018 and 009, temperature 20-25 deg.C, relative humidity 45% -65%.
1.3 laboratory instruments and reagents: a mouse cage with an interlayer, an operation scissors for dissection, a forceps, a meter ruler, an electronic scale and a plate; compound diphenoxylate (2.5 mg/tablet), Chinese ink (prepared from active carbon, acacia gum and water), distilled water, etc. Preparing a compound diphenoxylate solution: small intestine exercise test: adding distilled water into 5.0mg of compound diphenoxylate to 20mL, and mixing well to prepare the mixture when in use; defecation test: adding 10.0mg of compound diphenoxylate into distilled water to 20mL, and mixing well to prepare the mixture when in use. Preparation of ink (containing 5% of activated carbon powder and 10% of Arabic gum): accurately weighing 100g of Arabic gum, adding 800mL of water, boiling until the solution is transparent, weighing 50g of active carbon (powder) and adding the active carbon (powder) into the solution, boiling for three times, adding water to a constant volume of 1000mL after the solution is cooled, storing in a refrigerator at 4 ℃, and shaking uniformly before use.
1.4 dose design and formulation: the samples of the tested group and the control group are respectively set as two dosage groups of 1.46g/kg.Bw and 0.73g/kg.Bw, the dosages of the two dosage groups are respectively equal to 20 times and 10 times of the recommended dosage of a human body, and the other dosage group is set as a constipation model control group.
Sample preparation: 1.46g and 0.73g of samples of the tested group and the control group are respectively weighed and added with distilled water to 20mL to prepare suspensions with the concentration of 7.30 percent and 3.65 percent, and the suspensions are mixed evenly and prepared as the existing preparation for intragastric administration of the mice with medium and low doses.
2. Test method
2.1 the mice were divided into 2 test groups, each of which was randomly divided into a test group, a control group (both provided with two dose groups) and a constipation model control group, and the number of test animals was 10. One group of experiments is a small intestine movement experiment of a mouse, the other group of experiments is a defecation experiment of the mouse, samples with corresponding doses are orally given to a tested group and a control group once a day according to the doses, and the gavage volume is 20mL/kg. Constipation model the control group was given equal volume of distilled water for 7 consecutive days. Then, the measurement of each index is respectively carried out by the following method:
2.2 mouse intestinal motility test: the mice in each group were fasted without water deprivation for 16 hours, and the following morning were gavaged with compound diphenoxylate (5.0mg/kg. bw) to the model control group, the test group, and the control group. 30 minutes after the compound diphenoxylate is administered, the two dosage groups of the test group and the control group are respectively administered with ink (containing 5% of activated carbon powder and 10% of gum arabic mixture) containing corresponding dosage, the model control group is administered with ink for intragastric lavage (the lavage volume is 20mL/kg. Bw), animals are killed by removing the vertebra after 25 minutes, the abdominal cavity is opened to separate mesentery, the intestinal canal with the upper end from the lower end of the pylorus to the ileocecal part is subtracted, the intestinal canal is placed on a tray, the small intestine is lightly pulled to be a straight line, the length of the intestinal canal is measured to be the 'total length of the small intestine', the 'ink propelling length' is measured from the pylorus to the ink front edge, and the ink propelling rate is calculated according to the:
according to the formula
Data conversion was performed, where P is the ink propulsion rate, expressed in decimal, and analysis of variance was performed after data conversion (using SPSS20.0for Windows software).
2.3 mouse defecation test: mice in each group were fasted without water deprivation for 16 hours, and the following morning were gavaged with compound diphenoxylate (10mg/kg. bw) to two dose groups, model control group, test group and control group. 30 minutes after the compound diphenoxylate is administered, the test group and the control group are respectively administered with the mixture containing the corresponding dose of the ink (containing 5 percent of activated carbon powder and 10 percent of Arabic gum), and the model control group is administered with the ink for intragastric gavage (the intragastric gavage volume is 20mL/kg. Bw). Each animal is independently put into a small squirrel cage with an interlayer, and normally drinks and eats water. From the beginning of filling the ink, the first time of discharging the black feces of each mouse is recorded and the total amount of the black feces and the number of grains within 6 hours are counted.
2.4 results of the experiment
The mice are subjected to intragastric administration of samples with different doses, and the test is carried out after 7 days continuously, and no obvious diarrhea phenomenon is found in the mice of each dose group during the test period. And after the constipation model is successfully established, comparing the measured index results with the model control group respectively, and carrying out variance analysis.
2.4.1 results of mouse intestinal motility tests show that oral administration of the medium and low dose groups and the control group provided by the invention can improve the propelling speed of carbon powder in small intestine, and is in dose-effect relationship, and compared with a model control group, the dose group in the example 1 has significant difference (P <0.05), and the effect of each dose group in the example 1 is better than that of the same dose control group. The invention is provided with the plantain seed shell to replace the bunge cherry seed, which has better effect of promoting the small intestine of the mouse and obtains unexpected technical effect. Additional high dose-pair comparison experiments may be considered to validate the inference. The specific experimental results are shown in table 1 and fig. 1.
TABLE 1 Effect on intestinal motility in mice
P <0.05vs model control group
2.4.2 experimental results of mouse defecation experiments show that the first defecation time of the low and medium dose groups of the sample in the embodiment 1 of the invention is shorter than that of a constipation model control group and a same dose control group, and the medium dose group and the constipation model control group have significant difference (P is less than 0.05); in addition, the feces weights of the low and medium dosage groups of the sample in example 1 are larger than those of the constipation model control group and the same dosage control group, which indicates that the effect of promoting defecation is better after the plantain seed husk is added to replace bunge cherry seeds. Additional high dose-pair comparison experiments may be considered to validate the inference. The specific experimental results are shown in table 2 and fig. 2.
TABLE 2 test results for defecation time, fecal pellet count and weight of mice
P <0.05vs model control group
3. Subsequent testing
3.1 dosage design and preparation: the samples of the tested group and the samples of the control group are respectively set to be 2.18g/kg.Bw, the dosage of the samples is equal to 30 times of the recommended dosage of a human body, and a constipation model control group is additionally arranged.
Sample preparation: respectively weighing 2.18g of samples of the tested group and the control group, adding distilled water to 20mL to prepare suspension with the concentration of 10.90%, mixing uniformly, preparing immediately before use, and using as the gavage of a high-dose group mouse.
3.2 the mice were divided into 2 test groups, each of which was randomly divided into a test group, a control group and a constipation model control group, and the number of test animals was 10. One group of experiments is a small intestine movement experiment of a mouse, the other group of experiments is a defecation experiment of the mouse, samples with corresponding doses are orally given to a tested group and a control group once a day according to the doses, and the gavage volume is 20mL/kg. Constipation model the control group was given equal volume of distilled water for 7 consecutive days. Then, the measurement of each index is respectively carried out by the following method:
3.3 mouse intestinal motility test: the mice in each group were fasted without water deprivation for 16 hours, and the model control group, the test group and the control group were administered with compound diphenoxylate (5.0mg/kg. bw) by intragastric administration the next morning. 30 minutes after the compound diphenoxylate is administered, the tested group and the control group are respectively administered with ink (containing 5% of activated carbon powder and 10% of Arabic gum mixture) containing corresponding doses, the model control group is administered with ink for intragastric lavage (the lavage volume is 20mL/kg. Bw), the animals are killed by depolarization after 25 minutes, the abdominal cavity is opened to separate mesentery, the intestinal canal from the lower end of the pylorus to the ileocecum at the upper end is subtracted, the intestinal canal is placed on a tray, the small intestine is gently pulled to be a straight line, the length of the intestinal canal is measured to be the 'total length of the small intestine', the 'ink propulsion length' is measured from the pylorus to the ink front edge, and after data conversion, analysis of variance (using SPSS20.forWindows software) is carried.
3.4 mouse defecation test: mice in each group were fasted without water deprivation for 16 hours, and the next morning were gavaged with compound diphenoxylate (10mg/kg. bw) to the model control group, the test group, and the control group. 30 minutes after the compound diphenoxylate is administered, the test group and the control group are respectively administered with the mixture containing the corresponding dose of the ink (containing 5 percent of activated carbon powder and 10 percent of Arabic gum), and the model control group is administered with the ink for intragastric gavage (the intragastric volume is 20mL/kg. Bw). Each animal is independently put into a small squirrel cage with an interlayer, and normally drinks and eats water. From the beginning of filling the ink, the first time of discharging the black feces of each mouse is recorded and the total amount of the black feces and the number of grains within 6 hours are counted.
3.5 results of the experiment
The mice were gavaged with a high dose of the sample and tested 7 days later, during which no significant diarrhea was observed in the high dose group. And after the constipation model is successfully established, comparing the measured index results with the model control group respectively, and carrying out variance analysis.
3.5.1 mouse intestinal motility test results show that oral administration of the high-dose group of the example 1 and the high-dose group of the control group provided by the invention can improve the propelling speed of the carbon powder in the small intestine, and has a significant difference (P < 0.05). The invention shows that the effect of promoting the small intestine of the mouse to be pushed is better after the Plantago ovata forsk shells are added to replace the bunge cherry seeds, and the unexpected technical effect is achieved. The specific experimental results are shown in table 3.
TABLE 3 Effect on intestinal motility in mice
| Group of | Dosage (g/kg) | Animal number (only) | Ink push Rate (%) |
| Model control group | 0.00 | 10 | 39.80±3.77 |
| Control group | 2.18 | 10 | 50.21±3.51* |
| EXAMPLE 1 group | 2.18 | 10 | 55.59±3.42**# |
*P<0.05，**P<The control group of the 0.01vs model,#P<0.05vs control group
3.5.2 experimental results of mouse defecation experiments show that the first defecation time of the sample of the embodiment 1 group is shorter than that of a constipation model control group and a control group, and the samples have significant difference (P is less than 0.05) compared with the constipation model control group and the control group; in addition, the feces weight of the sample high-dose group in the example 1 is larger than that of the constipation model control group and the constipation model control group, which shows that the defecation promoting effect is better after the plantain husk is added to replace the bunge cherry seed. The results of the experiments are shown in Table 4.
TABLE 4 test results of defecation time, number of particles of stools and weight of mice
P <0.05vs model control; # P <0.05vs control group
The above embodiments are merely illustrative of the technical concept and features of the present invention, and the present invention is not limited thereto, and equivalent changes and modifications made according to the spirit of the present invention should be covered thereby.
Claims (10)
1. A health product with a function of relaxing bowels is characterized by comprising the following raw materials in parts by weight:
angelica, astragalus, bighead atractylodes rhizome, fructus cannabis, semen cassiae and plantain seed shell.
2. The health product with the function of relaxing bowels according to claim 1, which is characterized by comprising the following raw materials in parts by weight:
100-300 parts of angelica sinensis, 200-600 parts of astragalus membranaceus, 150-450 parts of bighead atractylodes rhizome, 150-450 parts of Plantago ovata forsk, 250-750 parts of fructus cannabis and 100-300 parts of semen cassiae.
3. The health product with the function of relaxing bowels according to claim 2, which is characterized by comprising the following raw materials in parts by weight:
100 parts of angelica, 200 parts of astragalus, 150 parts of bighead atractylodes rhizome, 150 parts of plantain seed shell, 250 parts of fructus cannabis and 100 parts of cassia seed.
4. The health product with the function of relaxing bowels according to claim 1, which is characterized by comprising the following raw materials in parts by weight:
300 parts of angelica, 600 parts of astragalus, 450 parts of bighead atractylodes rhizome, 450 parts of plantain seed husk, 750 parts of fructus cannabis and 300 parts of cassia seed.
5. The health product with the function of relaxing bowels according to claim 1, which is characterized by comprising the following raw materials in parts by weight:
200 parts of angelica, 400 parts of astragalus, 300 parts of bighead atractylodes rhizome, 300 parts of plantain seed shell, 500 parts of fructus cannabis and 200 parts of cassia seed.
6. A health product with a function of relaxing bowels is characterized by being prepared by the following method: (1) decocting radix Angelicae sinensis, radix astragali, Atractylodis rhizoma, fructus Cannabis and semen Cassiae in water, filtering, and mixing filtrates; concentrating under reduced pressure to obtain soft extract;
(2) taking the thick paste prepared in the step (1), drying under reduced pressure, crushing and sieving with a 80-mesh sieve for later use;
(3) respectively pulverizing Plantago ovata forsk, sucralose and maltodextrin, sieving with 80 mesh sieve, and mixing;
(4) uniformly mixing the extract powder of the medicinal materials in the step (2) and the powder in the step (3); then adding ethanol to prepare soft material, sieving and granulating, drying, grading, and preparing to obtain the granule.
7. The method for preparing a health product with a constipation relieving function according to any one of claims 1 to 3, comprising the steps of:
(1) extracting radix Angelicae sinensis, radix astragali, Atractylodis rhizoma, fructus Cannabis and semen Cassiae with water, filtering, and mixing filtrates; concentrating under reduced pressure to obtain soft extract;
(2) taking the thick paste prepared in the step (1), drying under reduced pressure, crushing and sieving for later use;
(3) pulverizing Plantago ovata forsk, sucralose and maltodextrin respectively, sieving, and mixing;
(4) uniformly mixing the extract powder of the medicinal materials in the step (2) and the powder in the step (3); then adding ethanol to prepare soft material, sieving and granulating, drying, grading, and preparing to obtain the granule.
8. The method for preparing a health product with a constipation relieving function according to any one of claims 1 to 3, comprising the steps of:
(1) firstly, extracting angelica sinensis, astragalus membranaceus, bighead atractylodes rhizome, fructus cannabis and semen cassiae with 6-15 times of water for 1-3 times, 1-2 hours each time, filtering, and combining filtrates; concentrating under reduced pressure to obtain soft extract;
(2) taking the thick paste prepared in the step (1), drying under reduced pressure, crushing, and sieving with a 80-100-mesh sieve for later use;
(3) respectively crushing Plantago ovata forsk, sucralose and maltodextrin, sieving with a sieve of 80-100 meshes, and uniformly mixing;
(4) uniformly mixing the extract powder of the medicinal materials in the step (2) and the powder in the step (3); then adding ethanol with volume concentration of 85% to prepare soft materials, granulating with 14-mesh sieve, drying, grading with 12-mesh sieve, and preparing into granule.
9. The method for preparing a health product with a function of relaxing bowels according to claim 8, wherein the step (1) comprises adding water 10 times the total weight of the herbs for the first time, decocting, refluxing or continuously refluxing for 1.5 hours, adding water 8 times the total weight of the herbs for the second time, refluxing or continuously refluxing for 1.5 hours, combining the decoctions, filtering, and combining the filtrates; concentrating under reduced pressure to obtain a thick paste with the relative density of 1.25-1.30 at 50 ℃.
10. The method for preparing a health product with a constipation relieving effect according to claim 8, wherein both the step (2) and the step (3) are passed through a 80 mesh sieve.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911248849.XA CN110916184A (en) | 2019-12-09 | 2019-12-09 | Health product with function of relaxing bowels and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911248849.XA CN110916184A (en) | 2019-12-09 | 2019-12-09 | Health product with function of relaxing bowels and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110916184A true CN110916184A (en) | 2020-03-27 |
Family
ID=69857586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911248849.XA Pending CN110916184A (en) | 2019-12-09 | 2019-12-09 | Health product with function of relaxing bowels and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110916184A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114504623A (en) * | 2022-04-19 | 2022-05-17 | 广东益可维生物技术有限公司 | Traditional Chinese medicine probiotic composite product for improving qi deficiency type constipation and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101991650A (en) * | 2009-08-21 | 2011-03-30 | 陈大刚 | Cassia seed and fructus cannabis capsules |
| CN107362213A (en) * | 2017-07-26 | 2017-11-21 | 中泰宜佳健康科技（北京）有限责任公司 | A kind of composition with bowel relaxing functions and preparation method thereof |
| CN107875255A (en) * | 2017-11-21 | 2018-04-06 | 符卓韬 | A kind of composition for relaxing bowel, losing weight |
-
2019
- 2019-12-09 CN CN201911248849.XA patent/CN110916184A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101991650A (en) * | 2009-08-21 | 2011-03-30 | 陈大刚 | Cassia seed and fructus cannabis capsules |
| CN107362213A (en) * | 2017-07-26 | 2017-11-21 | 中泰宜佳健康科技（北京）有限责任公司 | A kind of composition with bowel relaxing functions and preparation method thereof |
| CN107875255A (en) * | 2017-11-21 | 2018-04-06 | 符卓韬 | A kind of composition for relaxing bowel, losing weight |
Non-Patent Citations (1)
| Title |
|---|
| 杜丽东，等: "当归补血药对对血虚便秘模型大鼠的治疗作用", 《中药药理与临床》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114504623A (en) * | 2022-04-19 | 2022-05-17 | 广东益可维生物技术有限公司 | Traditional Chinese medicine probiotic composite product for improving qi deficiency type constipation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101269170A (en) | Medicament for treating climacteric syndrome and preparation method thereof | |
| CN110916184A (en) | Health product with function of relaxing bowels and preparation method thereof | |
| CN105878804A (en) | Application of medicinal and edible traditional Chinese medicine composition in preparation of foods with function of promoting digestion | |
| CN103142815B (en) | Purgative composition, preparation method and application thereof | |
| CN105343260B (en) | The drug for treating chronic ulcerative colitis | |
| CN105878559A (en) | Medicine composition or health-care food with bowel relaxing and constipation relieving efficacy | |
| CN105497111B (en) | Traditional Chinese medicine preparation for promoting lactation and preparation method thereof | |
| CN103520405A (en) | Pure Chinese medicinal health preservation preparation with effects of clearing heat, nourishing yin, moistening dryness, reinforcing qi, nourishing blood and relaxing bowels | |
| CN114869942B (en) | Traditional Chinese medicine composition for treating constipation and preparation method thereof | |
| CN104435666B (en) | Chinese medicine composition with functions of loosening bowel relieving constipation and its preparation method and application | |
| CN109999088A (en) | A kind of compound preparation and its application with effect of relaxing bowel | |
| CN102526410A (en) | Medicinal composition for treating functional constipation | |
| CN102266538B (en) | Traditional Chinese medicinal composition for treating damp-heat dysentery and preparation method thereof | |
| CN101167734A (en) | Composition capable of bidirectional adjusting gastrointestinal smooth muscle contraction | |
| CN1810265A (en) | Total sennoside extract for treating constipation and its extraction process | |
| CN106309736A (en) | Anti-fatigue traditional Chinese medicine composition as well as preparation method and application thereof | |
| CN102755588A (en) | Health care preparation for improving senile constipation | |
| CN110354196B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN105232854A (en) | Traditional Chinese medicine pill treating empirical constipation | |
| CN101757284B (en) | Traditional Chinese medicine patch for treating gastrointestinal diseases and preparation method thereof | |
| CN115025178B (en) | Application of orchid grass extract in preparation of medicine for preventing and/or treating constipation | |
| CN101766732A (en) | Chinese medicine composite for treating gastrointestinal diseases and preparation method thereof | |
| CN103272036A (en) | Intestine smoothing and constipation relieving traditional Chinese medicine composition | |
| CN108404068B (en) | Pharmaceutical composition for treating and/or preventing diarrhea and preparation method thereof | |
| CN108030847A (en) | A kind of pharmaceutical composition for treating constipation and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200327 |